CTX Trademark Information

Trademark by Cingulate Therapeutics LLC

Research and development services in the field of pharmaceuticals for the treatment of attention deficit/hyperactivity disorder (ADHD); conducting clinical trials for others in the field of pharmaceuticals for the treatment of attention- deficit/hyperactivity disorder (ADHD)

Classification Information

Use in Commerce Trademark - Applicant has provided proof of use of this mark in commerce to USPTO.

Primary Class: Class Details:
Class (042)
Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
First Use Anywhere:: 6/1/2014
First Use In Commerce: 6/1/2014
General Information
Word mark: CTX
Status/Status Date:
REGISTERED
6/18/2019
Serial Number: 87878032
Filing Date: 4/16/2018
Registration Number: 5778925
Registration Date: 6/18/2019
Goods and Services: Research and development services in the field of pharmaceuticals for the treatment of attention deficit/hyperactivity disorder (ADHD); conducting clinical trials for others in the field of pharmaceuticals for the treatment of attention- deficit/hyperactivity disorder (ADHD)
Mark Description: NOT AVAILABLE
Type Of Mark: Service Mark
Published For Opposition Date: 4/2/2019
Last Applicant/Owner:
Cingulate Therapeutics LLC
Kansas City, KS 66205
Mark Drawing Code: Standard Character Mark
Design Search:
(NO DATA)
Register Type: Principal
Disclaimer: (NOT AVAILABLE)
Correspondent:
MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND
701 PENNSYLVANIA AVENUE, N.W.
SUITE 900
WASHINGTON, DC 20004
Current Status:
REGISTERED
6/18/2019
Correspondent Search:
SUSAN NEUBERGER WELLER is a correspondent of CTX trademark.
Current Overall Rating:
RatingRatingRatingRatingRating

(0 review)

As seen on